PriceTargets.com logo

IM Cannabis - IMCC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.70 As of 12/6/2024 01:00 AM ET
▼ -0.12 (-4.26%)

This chart shows the closing price for IMCC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IM Cannabis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMCC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMCC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for IM Cannabis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.70.

This chart shows the closing price for IMCC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in IM Cannabis. This rating has held steady since March 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/30/2023Alliance Global PartnersDowngradeBuy ➝ Neutral
8/22/2022CormarkLower Target$360.00 ➝ $75.00
8/16/2022Alliance Global PartnersLower Target$360.00 ➝ $90.00
11/17/2021DesjardinsLower TargetBuyC$615.00 ➝ C$555.00
10/5/2021Roth CapitalInitiated CoverageBuy$480.00
8/18/2021DesjardinsLower TargetBuyC$630.00 ➝ C$615.00
8/17/2021Alliance Global PartnersLower TargetBuy$600.00 ➝ $480.00
7/13/2021DesjardinsInitiated CoverageBuy$630.00
6/10/2021Alliance Global PartnersInitiated CoverageBuy$600.00
(Data available from 12/8/2019 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/12/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/11/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/11/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/10/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/9/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/9/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/8/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/8/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

IM Cannabis logo
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $2.70
Low: $2.60
High: $2.74

50 Day Range

MA: $2.44
Low: $1.84
High: $3.99

52 Week Range

Now: $2.70
Low: $1.13
High: $8.10

Volume

32,230 shs

Average Volume

249,303 shs

Market Capitalization

$6.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of IM Cannabis?

The following Wall Street sell-side analysts have issued research reports on IM Cannabis in the last year:
View the latest analyst ratings for IMCC.

What is the current price target for IM Cannabis?

0 Wall Street analysts have set twelve-month price targets for IM Cannabis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IM Cannabis in the next year.
View the latest price targets for IMCC.

What is the current consensus analyst rating for IM Cannabis?

IM Cannabis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMCC.

What other companies compete with IM Cannabis?

Other companies that are similar to IM Cannabis include MiNK Therapeutics, RenovoRx, Lakeshore Biopharma, DURECT and Natural Alternatives International. Learn More about companies similar to IM Cannabis.

How do I contact IM Cannabis' investor relations team?

The company's listed phone number is 972-54-433-1111 and its investor relations email address is [email protected]. The official website for IM Cannabis is www.imcannabis.com. Learn More about contacing IM Cannabis investor relations.